Nicolas Chapuis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7468785/publications.pdf

Version: 2024-02-01

64 papers	4,070 citations	218677 26 h-index	144013 57 g-index
64 all docs	64 docs citations	64 times ranked	8084 citing authors

#	Article	IF	Citations
1	Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. Cell, 2020, 182, 1401-1418.e18.	28.9	663
2	Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood, 2015, 126, 1346-1356.	1.4	303
3	Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica, 2010, 95, 819-828.	3.5	240
4	Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood, 2013, 122, 3521-3532.	1.4	240
5	Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood, 2008, 111, 379-382.	1.4	234
6	PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies. Current Oncology Reports, 2012, 14, 129-138.	4.0	175
7	The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood, 2010, 116, 4262-4273.	1.4	173
8	PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia, 2008, 22, 1698-1706.	7.2	170
9	Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood, 2009, 114, 1618-1627.	1.4	169
10	High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica, 2011, 96, 1792-1798.	3.5	164
11	Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia. Clinical Cancer Research, 2010, 16, 5424-5435.	7.0	146
12	Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood, 2007, 110, 1025-1028.	1.4	129
13	Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica, 2010, 95, 415-423.	3.5	129
14	COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects. Angiogenesis, 2021, 24, 755-788.	7.2	114
15	Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia, 2010, 24, 1686-1699.	7.2	100
16	APR-246 induces early cell death by ferroptosis in acute myeloid leukemia. Haematologica, 2022, 107, 403-416.	3.5	95
17	LKB1/AMPK/mTOR signaling pathway in hematological malignancies: From metabolism to cancer cell biology. Cell Cycle, 2011, 10, 2115-2120.	2.6	94
18	IÎºB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia. Blood, 2010, 116, 4240-4250.	1.4	69

#	Article	IF	Citations
19	Targeting translation in acute myeloid leukemia: A new paradigm for therapy?. Cell Cycle, 2009, 8, 3893-3899.	2.6	51
20	Cytoplasmic proliferating cell nuclear antigen connects glycolysis and cell survival in acute myeloid leukemia. Scientific Reports, 2016, 6, 35561.	3.3	47
21	Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells. Oncotarget, 2016, 7, 35753-35767.	1.8	46
22	A dramatic fetal outcome following transplacental transfer of dasatinib. Anti-Cancer Drugs, 2012, 23, 754-757.	1.4	44
23	Pairing MCLâ€1 inhibition with venetoclax improves therapeutic efficiency of BH3â€mimetics in AML. European Journal of Haematology, 2020, 105, 588-596.	2.2	38
24	Oxidative Stress and Inflammatory Biomarkers for the Prediction of Severity and ICU Admission in Unselected Patients Hospitalized with COVID-19. International Journal of Molecular Sciences, 2021, 22, 7462.	4.1	36
25	A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset. Nature Communications, 2018, 9, 5455.	12.8	33
26	Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia. Frontiers in Oncology, 2019, 9, 405.	2.8	29
27	Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Haematologica, 2015, 100, 472-478.	3.5	28
28	Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leukemia and Lymphoma, 2008, 49, 2012-2014.	1.3	23
29	Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia. Oncogenesis, 2020, 9, 94.	4.9	23
30	Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes. Blood, 2017, 129, 484-496.	1.4	22
31	Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDSâ€Flow</scp> Cytometry Working Group. Cytometry Part B - Clinical Cytometry, 2023, 104, 77-86.	1.5	18
32	Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes. Haematologica, 2019, 104, 497-504.	3.5	17
33	Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis. Blood Cancer Journal, 2018, 8, 114.	6.2	16
34	Flow cytometric analysis of myelodysplasia: Preâ€analytical and technical issuesâ€”Recommendations from the European <scp>LeukemiaNet</scp>. Cytometry Part B - Clinical Cytometry, 2023, 104, 15-26.	1.5	16
35	Phenotypic landscape of granulocytes and monocytes by multiparametric flow cytometry: A prospective study of a 1â€tube panel strategy for diagnosis and prognosis of patients with MDS. Cytometry Part B - Clinical Cytometry, 2020, 98, 226-237.	1.5	12
36	Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia and Lymphoma, 2021, 62, 3558-3560.	1.3	12

#	Article	IF	Citations
37	RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia. Leukemia, 2022, 36, 1237-1252.	7.2	12
38	Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells. Leukemia Research, 2018, 71, 75-81.	0.8	11
39	ImmunoCluster provides a computational framework for the nonspecialist to profile high-dimensional cytometry data. ELife, 2021, 10, .	6.0	11
40	APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis. Oncotarget, 2016, 7, 14898-14911.	1.8	11
41	Immature/total granulocyte ratio improves early prediction of neurological outcome after out-of-hospital cardiac arrest: the MyeloScore study. Annals of Intensive Care, 2016, 6, 65.	4.6	10
42	The fraction of CD117/câ€KITâ€expressing erythroid precursors predicts ESA response in lowâ€risk myelodysplastic syndromes. Cytometry Part B - Clinical Cytometry, 2019, 96, 215-222.	1.5	10
43	CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation. British Journal of Haematology, 2019, 184, 625-633.	2.5	10
44	Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy. , 2015, 88, 101-109.		9
45	Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis. Blood Cancer Journal, 2021, 11, 62.	6.2	9
46	Salvage therapy of Autoimmune Thrombocytopenic Purpura revealing nonâ€Hodgkin Lymphoma by the thrombopoietin receptor agonist romiplostim. British Journal of Haematology, 2012, 156, 145-147.	2.5	7
47	Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters. Cancer Chemotherapy and Pharmacology, 2015, 76, 1033-1039.	2.3	7
48	Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients. EBioMedicine, 2022, 80, 104077.	6.1	7
49	Insulin Receptor A and IGF-1R in AML â€“ Letter. Cancer Research, 2010, 70, 7010.1-7010.	0.9	6
50	Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients. Pharmacological Research, 2016, 113, 709-718.	7.1	6
51	The eukaryotic Initiating Factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia. British Journal of Haematology, 2012, 156, 547-550.	2.5	5
52	MulticentricMFI30study: Standardization of flow cytometry analysis ofCD30expression innonâ€Hodgkinlymphoma. Cytometry Part B - Clinical Cytometry, 2020, 100, 488-496.	1.5	4
53	Lymphocyte Immunophenotyping and CD4/CD8 Ratio in Cerebrospinal Fluid for the Diagnosis of Sarcoidosis-related Uveitis. Ocular Immunology and Inflammation, 2021, 29, 290-298.	1.8	4
54	Sustained Leukemia-Free State and Molecular Response to Sorafenib in a Patient With Chronic Myelomonocytic Leukemia in Transformation Driven by Homozygous FLT3-ITD Malignant Hematopoiesis. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 347-350.	0.4	3

#	Article	IF	Citations
55	Too big for flow. Blood, 2019, 134, 576-576.	1.4	3
56	Plasma cell leukemia revealing a G6PD deficiency. Blood, 2016, 128, 3178-3178.	1.4	2
57	Etoposide-containing regimens for the treatment of critically ill patients with hematological malignancy-related hemophagocytic lymphohistiocytosis. Acta OncolÃ³gica, 2022, 61, 608-610.	1.8	2
58	Paraneoplastic Hyperleukocytosis Mimicking Hematologic Malignancy Revealing a Localized Lung Cancer. Annals of Thoracic Surgery, 2020, 109, e203-e206.	1.3	1
59	A meal served cold. British Journal of Haematology, 2020, 190, 12-12.	2.5	1
60	Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications. Diagnostics, 2022, 12, 1659.	2.6	1
61	A pernicious mean corpuscular volume. Blood, 2018, 131, 472-472.	1.4	0
62	Pegylated liposomal doxorubicin-induced palmar plantar erythrodyesthesia: Identification of risks factors.. Journal of Clinical Oncology, 2015, 33, e13569-e13569.	1.6	0
63	Clonal B-Cell Lymphocytosis with Marginal Zone Features and Splenic Marginal Zone Lymphoma Share a Similar Cytogenetic and Mutational Profile. Blood, 2016, 128, 2962-2962.	1.4	0
64	Architectural and Functional Heterogeneity of Hematopoietic Stem/Progenitor Cells in Non-Del(5q) Myelodysplastic Syndromes. Blood, 2016, 128, 3153-3153.	1.4	0